Sequencing Abiraterone and Enzalutamide in mCRPC
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses sequencing abiraterone and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Clinical Pearls
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses sequencing abiraterone and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
- This study is a retrospective analysis aiming to characterize the activity of abiraterone following enzalutamide and vice versa
- Data sets like these are becoming increasingly important and speak to potential resistance that evolves when a patient receives one drug or the other for mCRPC
- This study, as well as others, have shown that receiving one drug may compromise the efficacy of the second
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
